Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S

被引：50

作者：

Li, Qiannan ^{[1
]}

Zhang, Tao ^{[2
]}

Li, Shiliang ^{[1
]}

Tong, Linjiang ^{[2
]}

Li, Junyu ^{[1
]}

Su, Zhicheng ^{[1
]}

Feng, Fang ^{[2
]}

Sun, Deheng ^{[1
]}

Tong, Yi ^{[1
]}

Wang, Xia ^{[1
]}

Zhao, Zhenjiang ^{[1
]}

Zhu, Lili ^{[1
]}

Ding, Jian ^{[2
]}

Li, Honglin ^{[1
]}

Xie, Hua ^{[2
]}

Xu, Yufang ^{[1
]}

机构：

[1] East China Univ Sci & Technol, Sch Pharm, State Key Lab Bioreactor Engn, Shanghai Key Lab New Drug Design, Shanghai 200237, Peoples R China

[2] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Div Antitumor Pharmacol, Shanghai 201203, Peoples R China

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2019年 / 10卷 / 06期

基金：

中国国家自然科学基金;

关键词：

EGFR; mutant; inhibitor; C797S; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; MUTATIONS; GEFITINIB; AZD9291;

D O I：

10.1021/acsmedchemlett.8b00564

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

In this paper, we describe the discovery and optimization of a series of noncovalent reversible epidermal growth factor receptor inhibitors of EGFR(L858R/T790M/C797S). One of the most promising compounds, 25g, inhibited the enzymatic activity of EGFR(L8S8R/T790M/C797S) with an IC50 value of 2.2 nM. Cell proliferation assays showed that 25g effectively and selectively inhibited the growth of EGFR(L858R/T790M/C797S)-dependent cells. This series of compounds, which occupy both the ATP binding site and the allosteric site of the EGFR kinase, may serve as a basis for the development of fourth-generation EGFR inhibitors for L858R/T790M/C797S mutants.

引用

页码：869 / 873

页数：9

共 50 条

[21] Development of triple mutant T790M/C797S allosteric EGFR inhibitors: a computational approach
Karnik, Kshipra S.
Sarkate, Aniket P.
Lokwani, Deepak K.
Narula, Ishudeep S.
Burra, Prasad V. L. S.
Wakte, Pravin S.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (15): : 5376 - 5398
[22] 2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFRL858R/T790M
Chan, Shingpan
Han, Kun
Qu, Rong
Tong, Linjiang
Li, Yingjun
Zhang, Zhang
Cheng, Huimin
Lu, Xiaoyun
Patterson, Adam
Smaill, Jeff
Ren, Xiaomei
Ding, Jian
Xie, Hua
Ding, Ke
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (19) : 4277 - 4281
[23] EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib
Kobayashi, Yoshihisa
Fujino, Toshio
Nishino, Masaya
Koga, Takamasa
Chiba, Masato
Sesumi, Yuichi
Ohara, Shuta
Shimoji, Masaki
Tomizawa, Kenji
Takemoto, Toshiki
Mitsudomi, Tetsuya
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (05) : 727 - 731
[24] Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant
Guenther, Marcel
Juchum, Michael
Kelter, Gerhard
Fiebig, Heiner
Laufer, Stefan
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (36) : 10890 - 10894
[25] Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)
Shen, Jiayi
Zhang, Tao
Zhu, Su-Jie
Sun, Min
Tong, Linjiang
Lai, Mengzhen
Zhang, Rong
Xu, Wei
Wu, Ruibo
Ding, Jian
Yun, Cai-Hong
Xie, Hua
Lu, Xiaoyun
Ding, Ke
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (15) : 7302 - 7308
[26] Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site
Gunther, Marcel
Lategahn, Jonas
Juchum, Michael
Doring, Eva
Keul, Marina
Engel, Julian
Tumbrink, Hannah L.
Rauh, Daniel
Laufer, Stefan
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (13) : 5613 - 5637
[27] Synthesis and Evaluation of 2-Amine-4-oxyphosaniline Pyrimidine Derivatives as EGFR L858R/T790M/C797S Mutant Inhibitors
Zhang, Mingguang
Yang, Yang
Wang, Yunyun
Wang, Jia
Wu, Hongyan
Zhu, Yongqiang
CHEMICAL & PHARMACEUTICAL BULLETIN, 2023, 71 (02) : 140 - 147
[28] Discovery of potent and selective next-generation EGFR inhibitors with activity against single, double, and triple mutant EGFR variants including T790M and C797S
Huang, Wei-Sheng
Nadworny, Sara
Narasimhan, Narayana
Eyermann, Charles J.
Dalgarno, David C.
Rivera, Victor M.
Shakespeare, William C.
CANCER RESEARCH, 2022, 82 (12)
[29] Exploration of novel dihydroquinoxalinone derivatives as EGFRL858R/T790M tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer
Cao, Yu
Lu, Xixuan
Fu, Liping
Shi, Tao
Zhang, Chong
Zeng, Linghui
Zhang, Jiankang
Shao, Jiaan
Xi, Jianjun
Pan, Zongfu
Liu, Shourong
Zhu, Huajian
BIOORGANIC CHEMISTRY, 2023, 135
[30] Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S
Wang, Tong-Hong
Leu, Yann-Lii
Chen, Chin-Chuan
Li, Hsin-Jung
Yang, Shuenn-Chen
Huang, Kuo-Yen
Chen, Chi-Yuan
PHYTOTHERAPY RESEARCH, 2022, 36 (05) : 2116 - 2126

← 1 2 3 4 5 →